SRB Corp’s AbbVie ABBV Stock Holding History

SRB Corp’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,398	Closed	-$382K	–	98
2023 Q1	$382K	Sell	2,398 -640	-21%	-$97.8K	0.02%	25
2022 Q4	$490K	Hold	3,038	–	–	0.03%	16
2022 Q3	$408K	Sell	3,038 -7,049	-70%	-$1.01M	0.03%	31
2022 Q2	$1.54M	Sell	10,087 -1,840	-15%	-$281K	0.1%	24
2022 Q1	$1.93M	Hold	11,927	–	–	0.11%	13
2021 Q4	$1.61M	Sell	11,927 -2,329	-16%	-$275K	0.08%	16
2021 Q3	$1.54M	Buy	+14,256	New	+$1.63M	0.09%	81
2020 Q3	–	Sell	-5,432	Closed	-$533K	–	147
2020 Q2	$533K	Sell	5,432 -240	-4%	-$21.1K	0.04%	60
2020 Q1	$432K	Buy	+5,672	New	+$483K	0.04%	49
2019 Q3	–	Sell	-6,048	Closed	-$440K	–	160
2019 Q2	$440K	Buy	+6,048	New	+$475K	0.04%	164
2019 Q1	–	Sell	-6,263	Closed	-$577K	–	120
2018 Q4	$577K	Buy	+6,263	New	+$551K	0.06%	16

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SRB Corp's ABBV Position: Q2 2023 in Review

SRB Corp sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 2,398 shares — an estimated $382K sold.

SRB Corp first reported a position in ABBV in Q4 2018 and held it in 11 quarters. The position peaked at $1.93M in Q1 2022. 3,077 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

SRB Corp reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
SRB Corp sold 2,398 AbbVie shares in Q2 2023, an estimated $382K.
SRB Corp first reported a position in AbbVie in Q4 2018 and held it in 11 quarters.
SRB Corp's AbbVie position peaked at $1.93M in Q1 2022.
3,077 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on SRB Corp's 13F filing for Q2 2023, filed 14 Aug 2023.